Veracyte Financials
Veracyte (VCYT) reported $517.1M in revenue for fiscal year 2025, up 16.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Veracyte’s model is now scaling through fixed-cost absorption, with rising gross margin turning growth into cash rather than burn.
From FY2023 to FY2025, gross margin widened to70.1% while SG&A stayed essentially flat near$111M . That let incremental revenue carry much more of the cost base, and free cash flow of$126.6M exceeded net income of$66.4M , indicating the move into profitability is showing up in cash rather than remaining an accounting result.
Profitability improved without starving investment: R&D rose to
The balance sheet is self-funded and unusually liquid, with
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Veracyte's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Veracyte has an operating margin of 11.2%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 38/100, indicating healthy but not exceptional operating efficiency. This is up from 3.6% the prior year.
Veracyte's revenue surged 16.0% year-over-year to $517.1M, reflecting rapid business expansion. This strong growth earns a score of 81/100.
Veracyte carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.15, Veracyte holds $8.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.
Veracyte converts 24.5% of revenue into free cash flow ($126.6M). This strong cash generation earns a score of 85/100.
Veracyte's ROE of 5.1% shows moderate profitability relative to equity, earning a score of 33/100. This is up from 2.1% the prior year.
Veracyte scores 21.65, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.4B) relative to total liabilities ($96.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Veracyte passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Veracyte generates $2.05 in operating cash flow ($136.3M OCF vs $66.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Veracyte generated $517.1M in revenue in fiscal year 2025. This represents an increase of 16.0% from the prior year.
Veracyte's EBITDA was $79.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.0% from the prior year.
Veracyte reported $66.4M in net income in fiscal year 2025. This represents an increase of 175.5% from the prior year.
Veracyte earned $0.82 per diluted share (EPS) in fiscal year 2025. This represents an increase of 164.5% from the prior year.
Cash & Balance Sheet
Veracyte generated $126.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 98.5% from the prior year.
Veracyte held $362.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Veracyte's gross margin was 70.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.2 percentage points from the prior year.
Veracyte's operating margin was 11.2% in fiscal year 2025, reflecting core business profitability. This is up 7.5 percentage points from the prior year.
Veracyte's net profit margin was 12.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.4 percentage points from the prior year.
Veracyte's ROE was 5.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.0 percentage points from the prior year.
Capital Allocation
Veracyte invested $70.8M in research and development in fiscal year 2025. This represents an increase of 2.2% from the prior year.
Veracyte invested $9.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 14.3% from the prior year.
Not reported for fiscal year 2025.
VCYT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $561.9M | $517.1M+16.0% | $445.8M+23.5% | $361.1M+21.8% | $296.5M+35.1% | $219.5M+86.8% | $117.5M-2.4% | $120.4M+30.8% | $92.0M+27.9% | $72.0M+10.6% | $65.1M+31.5% | $49.5M+29.6% | $38.2M+74.5% | $21.9M+88.2% | $11.6M+339.6% | $2.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $36.1M+9.1% | $33.1M+17.3% | $28.2M+10.7% | $25.5M+18.4% | $21.5M+29.5% | $16.6M+31.7% | $12.6M+66.2% | $7.6M+159.3% | $2.9M |
| Gross Profit | $403.0M | $362.5M+21.6% | $298.1M+29.8% | $229.7M+30.7% | $175.7M | N/A | N/A | $84.3M+43.0% | $58.9M+34.7% | $43.8M+10.4% | $39.6M+41.5% | $28.0M+29.8% | $21.6M+132.7% | $9.3M+129.4% | $4.0M+1544.3% | -$280K |
| R&D Expenses | $93.4M | $70.8M+2.2% | $69.3M+20.9% | $57.3M+41.1% | $40.6M+36.1% | $29.8M+73.5% | $17.2M+15.8% | $14.9M+0.2% | $14.8M+6.8% | $13.9M-9.4% | $15.3M+19.8% | $12.8M+30.5% | $9.8M+25.5% | $7.8M+18.2% | $6.6M-1.1% | $6.7M |
| SG&A Expenses | $95.8M | $110.8M+0.2% | $110.6M+28.3% | $86.2M+17.8% | $73.2M-27.8% | $101.4M+175.9% | $36.7M+26.5% | $29.0M+21.1% | $24.0M+3.8% | $23.1M-2.9% | $23.8M+5.3% | $22.6M+19.8% | $18.9M+55.8% | $12.1M+52.8% | $7.9M+47.4% | $5.4M |
| Operating Income | $105.8M | $57.8M+257.9% | $16.1M+118.8% | -$85.8M-108.8% | -$41.1M+49.8% | -$81.9M-131.4% | -$35.4M-133.9% | -$15.1M+32.0% | -$22.2M+16.2% | -$26.5M+7.9% | -$28.8M+13.9% | -$33.5M-15.4% | -$29.0M-25.2% | -$23.2M-22.4% | -$18.9M-24.0% | -$15.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $229K-66.2% | $677K-65.5% | $2.0M-60.3% | $4.9M+79.2% | $2.8M+629.4% | $378K-13.9% | $439K+88.4% | $233K | N/A | N/A |
| Income Tax | $1.5M | $1.8M+15.1% | $1.6M+172.7% | -$2.2M-1760.2% | $133K+102.2% | -$6.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Net Income | $114.5M | $66.4M+175.5% | $24.1M+132.4% | -$74.4M-103.3% | -$36.6M+51.6% | -$75.6M-116.6% | -$34.9M-177.1% | -$12.6M+45.2% | -$23.0M+25.8% | -$31.0M+1.1% | -$31.4M+7.0% | -$33.7M-14.7% | -$29.4M-14.8% | -$25.6M-37.2% | -$18.6M-29.1% | -$14.4M |
| EPS (Diluted) | — | $0.82+164.5% | $0.31+130.4% | -$1.02-100.0% | -$0.51+54.1% | -$1.11-68.2% | -$0.66-144.4% | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VCYT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+8.2% | $1.3B+16.6% | $1.1B-3.6% | $1.2B-2.6% | $1.2B+159.8% | $457.2M+66.1% | $275.2M+128.1% | $120.6M+53.3% | $78.7M-22.1% | $101.0M+34.3% | $75.2M+16.1% | $64.8M-18.6% | $79.6M+317.6% | $19.1M | N/A |
| Current Assets | $488.4M+31.2% | $372.3M+30.3% | $285.6M+14.9% | $248.6M+2.3% | $243.1M-35.3% | $375.7M+100.2% | $187.7M+93.6% | $97.0M+79.8% | $53.9M-26.8% | $73.6M+53.7% | $47.9M+10.5% | $43.3M-43.3% | $76.4M+366.4% | $16.4M | N/A |
| Cash & Equivalents | $362.6M+51.7% | $239.1M+10.5% | $216.5M+40.3% | $154.2M-10.9% | $173.2M-50.4% | $349.4M+119.3% | $159.3M+104.3% | $78.0M+130.1% | $33.9M-42.8% | $59.2M+51.5% | $39.1M+11.6% | $35.0M-50.8% | $71.2M+408.6% | $14.0M+85.1% | $7.6M |
| Inventory | $20.5M-5.5% | $21.8M+34.9% | $16.1M+12.8% | $14.3M+27.3% | $11.2M+141.0% | $4.7M-31.6% | $6.8M+100.1% | $3.4M-36.1% | $5.3M+53.2% | $3.5M-7.8% | $3.8M+1.9% | $3.7M+44.0% | $2.6M+144.5% | $1.1M | N/A |
| Accounts Receivable | $44.7M-4.0% | $46.5M+15.2% | $40.4M-8.3% | $44.0M+6.2% | $41.5M+124.6% | $18.5M-4.5% | $19.3M+46.8% | $13.2M+3.6% | $12.7M+45.2% | $8.8M+150.0% | $3.5M+14.9% | $3.0M+166.8% | $1.1M+100.9% | $569K | N/A |
| Goodwill | $767.2M+2.9% | $745.8M+6.1% | $703.0M+1.0% | $695.9M-1.7% | $707.9M+25878.1% | $2.7M0.0% | $2.7M+157.8% | $1.1M0.0% | $1.1M0.0% | $1.1M0.0% | $1.1M0.0% | $1.1M | N/A | N/A | N/A |
| Total Liabilities | $96.4M-22.3% | $124.1M+75.2% | $70.8M-12.8% | $81.2M-11.0% | $91.3M+154.1% | $35.9M+0.5% | $35.8M-12.5% | $40.9M-1.4% | $41.4M0.0% | $41.5M+72.8% | $24.0M+2.3% | $23.5M+1.2% | $23.2M-70.1% | $77.5M | N/A |
| Current Liabilities | $59.9M-23.8% | $78.6M+28.4% | $61.2M-2.2% | $62.6M-2.4% | $64.2M+282.3% | $16.8M-3.9% | $17.5M+33.8% | $13.1M+8.6% | $12.0M+4.3% | $11.5M-21.7% | $14.7M-14.1% | $17.1M+11.4% | $15.4M+71.1% | $9.0M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | $0-100.0% | $810K+16.7% | $694K-97.1% | $23.9M-4.1% | $24.9M+0.1% | $24.9M+399.4% | $5.0M+1.4% | $4.9M+0.5% | $4.9M | N/A | N/A |
| Total Equity | $1.3B+11.4% | $1.2B+12.6% | $1.0B-2.9% | $1.1B-1.9% | $1.1B+160.3% | $421.2M+75.9% | $239.5M+200.2% | $79.8M+114.3% | $37.2M-37.5% | $59.6M+16.3% | $51.3M+23.9% | $41.4M-26.7% | $56.4M+196.5% | -$58.5M-43.4% | -$40.8M |
| Retained Earnings | -$377.6M+14.9% | -$444.0M+5.2% | -$468.1M-18.9% | -$393.7M-10.2% | -$357.2M-26.8% | -$281.6M-14.2% | -$246.7M-5.4% | -$234.1M-10.9% | -$211.1M-17.2% | -$180.1M-21.1% | -$148.7M-29.3% | -$115.0M-34.3% | -$85.6M-42.6% | -$60.1M | N/A |
VCYT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $178.4M | $136.3M+81.5% | $75.1M+69.8% | $44.2M+486.9% | $7.5M+123.8% | -$31.6M-225.6% | -$9.7M-200.5% | -$3.2M+76.1% | -$13.5M+43.5% | -$23.9M+14.5% | -$28.0M-3.8% | -$27.0M+2.4% | -$27.6M-44.2% | -$19.2M-167.3% | -$7.2M+47.0% | -$13.5M |
| Capital Expenditures | $12.4M | $9.7M-14.3% | $11.3M+13.3% | $10.0M+16.5% | $8.5M+59.0% | $5.4M+89.5% | $2.8M+2.9% | $2.8M+47.1% | $1.9M+6.8% | $1.8M-58.3% | $4.2M-31.7% | $6.2M+204.6% | $2.0M+52.0% | $1.3M-8.9% | $1.5M+429.7% | $276K |
| Free Cash Flow | $166.0M | $126.6M+98.5% | $63.8M+86.2% | $34.3M+3478.8% | -$1.0M+97.3% | -$37.0M-194.8% | -$12.5M-109.6% | -$6.0M+61.1% | -$15.4M+40.0% | -$25.7M+20.3% | -$32.2M+2.8% | -$33.1M-11.7% | -$29.7M-44.7% | -$20.5M-137.5% | -$8.6M+37.5% | -$13.8M |
| Investing Cash Flow | -$98.7M | -$9.2M+83.6% | -$56.3M-472.4% | $15.1M+151.4% | -$29.4M+96.0% | -$739.2M-19165.2% | -$3.8M+91.0% | -$42.7M-2180.3% | -$1.9M-42.5% | -$1.3M+68.8% | -$4.2M+37.1% | -$6.7M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $338K | -$4.2M-186.1% | $4.9M+72.9% | $2.8M-18.8% | $3.5M-99.4% | $596.3M+192.9% | $203.6M+59.9% | $127.3M+113.9% | $59.5M+27393.1% | -$218K-100.4% | $52.3M+38.7% | $37.7M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VCYT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.1%+3.2pp | 66.9%+3.3pp | 63.6%+4.4pp | 59.2% | N/A | N/A | 70.0%+6.0pp | 64.0%+3.2pp | 60.8%-0.1pp | 60.9%+4.3pp | 56.6%0.0pp | 56.5%+14.1pp | 42.4%+7.6pp | 34.8%+45.4pp | -10.6% |
| Operating Margin | 11.2%+7.5pp | 3.6%+27.4pp | -23.8%-9.9pp | -13.9%+23.5pp | -37.3%-7.2pp | -30.1%-17.6pp | -12.6%+11.6pp | -24.2%+12.7pp | -36.9%+7.4pp | -44.3%+23.4pp | -67.6%+8.3pp | -75.9% | -105.9% | -162.8% | -577.2% |
| Net Margin | 12.8%+7.4pp | 5.4%+26.0pp | -20.6%-8.3pp | -12.3%+22.1pp | -34.4%-4.7pp | -29.7%-19.2pp | -10.5%+14.5pp | -25.0%+18.1pp | -43.1%+5.1pp | -48.2%+19.9pp | -68.1%+8.8pp | -76.9% | -116.9% | -160.4% | -546.1% |
| Return on Equity | 5.1%+3.0pp | 2.1%+9.2pp | -7.1%-3.7pp | -3.4%+3.5pp | -6.9%+1.4pp | -8.3%-3.0pp | -5.3%+23.6pp | -28.8%+54.4pp | -83.3%-30.7pp | -52.6%+13.1pp | -65.8%+5.2pp | -71.0%-25.7pp | -45.3% | N/A | N/A |
| Return on Assets | 4.7%+2.9pp | 1.8%+8.5pp | -6.7%-3.5pp | -3.2%+3.2pp | -6.4%+1.3pp | -7.6%-3.1pp | -4.6%+14.5pp | -19.1%+20.4pp | -39.4%-8.4pp | -31.0%+13.8pp | -44.8%+0.5pp | -45.3%-13.2pp | -32.1%+65.7pp | -97.8% | N/A |
| Current Ratio | 8.15+3.4x | 4.73+0.1x | 4.66+0.7x | 3.97+0.2x | 3.79-18.6x | 22.39+11.6x | 10.74+3.3x | 7.42+2.9x | 4.48-1.9x | 6.38+3.1x | 3.25+0.7x | 2.53-2.4x | 4.97+3.1x | 1.82 | N/A |
| Debt-to-Equity | 0.070.0x | 0.110.0x | 0.070.0x | 0.08+0.1x | 0.000.0x | 0.000.0x | 0.00-0.3x | 0.30-0.4x | 0.67+0.3x | 0.42+0.3x | 0.100.0x | 0.120.0x | 0.09 | N/A | N/A |
| FCF Margin | 24.5%+10.2pp | 14.3%+4.8pp | 9.5%+9.8pp | -0.3%+16.5pp | -16.9%-6.2pp | -10.7%-5.7pp | -5.0%+11.8pp | -16.7%+18.9pp | -35.7%+13.8pp | -49.5%+17.5pp | -66.9%+10.7pp | -77.6%+16.0pp | -93.6%-19.4pp | -74.2% | -521.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Veracyte Ranks
Frequently Asked Questions
What is Veracyte's annual revenue?
Veracyte (VCYT) reported $517.1M in total revenue for fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Veracyte's revenue growing?
Veracyte (VCYT) revenue grew by 16.0% year-over-year, from $445.8M to $517.1M in fiscal year 2025.
Is Veracyte profitable?
Yes, Veracyte (VCYT) reported a net income of $66.4M in fiscal year 2025, with a net profit margin of 12.8%.
What is Veracyte's EBITDA?
Veracyte (VCYT) had EBITDA of $79.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Veracyte's gross margin?
Veracyte (VCYT) had a gross margin of 70.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Veracyte's operating margin?
Veracyte (VCYT) had an operating margin of 11.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Veracyte's net profit margin?
Veracyte (VCYT) had a net profit margin of 12.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Veracyte's return on equity (ROE)?
Veracyte (VCYT) has a return on equity of 5.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Veracyte's free cash flow?
Veracyte (VCYT) generated $126.6M in free cash flow during fiscal year 2025. This represents a 98.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Veracyte's operating cash flow?
Veracyte (VCYT) generated $136.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Veracyte's total assets?
Veracyte (VCYT) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Veracyte's capital expenditures?
Veracyte (VCYT) invested $9.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Veracyte spend on research and development?
Veracyte (VCYT) invested $70.8M in research and development during fiscal year 2025.
What is Veracyte's current ratio?
Veracyte (VCYT) had a current ratio of 8.15 as of fiscal year 2025, which is generally considered healthy.
What is Veracyte's debt-to-equity ratio?
Veracyte (VCYT) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Veracyte's return on assets (ROA)?
Veracyte (VCYT) had a return on assets of 4.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Veracyte's Altman Z-Score?
Veracyte (VCYT) has an Altman Z-Score of 21.65, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Veracyte's Piotroski F-Score?
Veracyte (VCYT) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Veracyte's earnings high quality?
Veracyte (VCYT) has an earnings quality ratio of 2.05x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Veracyte?
Veracyte (VCYT) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.